**Education and Professional Experience:** 2022.05-Present, Director, Department of Musculoskeletal Oncology, The First Affiliated Hospital, Sun Yat-sen University 2022.01-Present, Professor, The First Affiliated Hospital, Sun Yat-sen University 2018.01-2021.12, Chief Physician, The First Affiliated Hospital, Sun Yat-sen University 2013.01-2018.05, Associate Chief Physician, The First Affiliated Hospital, Sun Yat-sen University 2011.01-2012.12, Attending Physician, The First Affiliated Hospital, Sun Yat-sen University 2007.07-2010.12, Resident Physician, The First Affiliated Hospital, Sun Yat-sen University 2004, 2018, Visiting Scholar, Rizzoli Orthopedic Institute, Italy (Bone Tumor Center) 2001.9-2007.6, Ph.D., Sun Yat-sen University **Professional Affiliations:** Standing Committee Member & Secretary, Sarcoma Committee, Chinese Anti-Cancer Association Deputy Head, Youth Group, Bone Tumor and Bone Metastasis Committee, Chinese Anti-Cancer Association Deputy Head, Innovation and Transformation Group, Sarcoma Committee, Chinese Anti-Cancer Association Deputy Head, Second Session of Drug and Precision Therapy Group, Bone Tumor and Bone Metastasis Committee, Chinese Anti-Cancer Association Standing Committee Member, Second Session of Repair and Reconstruction Group, Bone Tumor and Bone Metastasis Committee, Chinese Anti-Cancer Association Vice Chairman, Bone Tumor Professional Branch, Guangdong Medical Doctor Association Chairman, Integrated Diagnosis and Treatment Group, Bone Tumor Professional Branch, Guangdong Medical Doctor Association Standing Committee Member, 11th Committee, Orthopedics Branch, Guangdong Medical Association Chairman, Integrated Diagnosis and Treatment Committee for Bone and Soft Tissue Tumors, Guangdong Health Management Association Vice Chairman, Bone and Soft Tissue Tumor Committee, Guangdong Clinical Medicine Association Member, Bone Tumor Group, Orthopedic Innovation and Transformation Committee, Chinese Research Hospital Association Standing Committee Member & Executive Secretary, 4th Committee, Geriatric Orthopedics Branch, Chinese Gerontology and Geriatrics Society Outstanding Young Medical Talent of Guangdong Province Ke Lin Elite Talent, The First Affiliated Hospital, Sun Yat-sen University **Publications:** Published over 40 clinical and basic research articles in the field of bone tumors, particularly osteosarcoma, including over 40 SCI articles. Representative works published in top oncology journals such as *Nature Cell Biology* (a Nature journal), *Clinical Cancer Research*, *Signal Transduction and Targeted Therapy*, *Acta Pharmaceutica Sinica B*, and *Cancer Prev Res*. 1. Junqiang Yin# (Co-first author). Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. *Nature Cell Biology*. 2020 Jul;22(7):868-881. (Impact Factor: 28.824) 2. Junqiang Yin* (Co-corresponding author). AHA1 upregulates IDH1 and metabolic activity to promote growth and metastasis and predicts prognosis in osteosarcoma. *Signal Transduct Target Ther*. 2021 Jan 20;6(1):25. (Impact Factor: 18.187) 3. Junqiang Yin# (Co-first author). Author Correction: Chromosomal translocation-derived aberrant Rab22a drives metastasis of osteosarcoma. *NATURE CELL BIOLOGY*. 2024 Mar;26(3):490. (Impact Factor: 17.3) 4. Junqiang Yin* (Corresponding author). SNPs Give LACTB Oncogene-Like Functions and Prompt Tumor Progression via Dual-Regulating p53. *Advanced Science*. 2024 Nov;11(43):e2405907. (Impact Factor: 14.3) 5. Junqiang Yin* (Co-corresponding author). Targeting Super-Enhancer–Associated Oncogenes in Osteosarcoma with THZ2, a Covalent CDK7 Inhibitor. *Clin Cancer Res*. 2020 Jun 1;26(11):2681-2692. (Impact Factor: 12.531) 6. Junqiang Yin* (Co-corresponding author). The FAPa-activated prodrug Z-GP-DAVLBH inhibits the growth and pulmonary metastasis of osteosarcoma cells by suppressing the AXL pathway. *Acta Pharmaceutica Sinica B* (ISSN: 2211-3835). Article. 2022 Mar;12(3):1288-1304. (Impact Factor: 11.47) 7. Junqiang Yin* (Co-corresponding author). Metal phenolic networks-driven bufalin homodimeric prodrug nano-coassemblies for ferroptosis-augmented tumor therapy. *Journal of Controlled Release*. 2025 Jul 10:383:113814. (CAS JCR Quartile: Q1 in Medicine (Pharmacy), IF: 11.5) 8. Junqiang Yin* (Corresponding author). Tumor-informed deep sequencing of ctDNA detects minimal residual disease and predicts relapse in osteosarcoma. *EClinicalMedicine*. 2024 Jun 20:73:102697. (CAS Q1, IF: 9.6) **Other Major Achievements (e.g., Awards):** 1. 2020, "Construction Technology and Application of Patient-Derived Tumor Xenograft (PDX) Models", First Prize of Guangdong Animal Science and Technology Award, 8th Completer. 2. 2010, "Proteomics Study of Osteosarcoma Specific Antigens and Their Diagnostic and Therapeutic Applications", Third Prize of Guangzhou Science and Technology Award, 4th Completer. 3. April 2023, "Innovation and Clinical Application of Precision Diagnosis and Treatment Technology for Osteosarcoma", First Prize of Guangdong Precision Medicine Science and Technology Award, 2nd Completer. 4. 2020, "Construction Technology and Application of Patient-Derived Tumor Xenograft (PDX) Models", First Prize of Guangdong Animal Science and Technology Award, 7th Completer. 5. November 1, 2025, "Promotion and Application of New Technologies for Sarcoma Diagnosis and Treatment", First Prize of Guangzhou Major Clinical Medical Achievement Award, 1st Completer.